Lung Biology and Pathophysiology

Yutong Zhao is a Professor of Physiology and Cell Biology at The Ohio State University. He received his clinical medical degree from Dalian Medical University in China and PhD degree from Gifu University School of Medicine in Japan. He was trained in biochemistry, molecular biology, and active lipid signaling during his PhD student period. He joined a pulmonary postdoctoral training program at Johns Hopkins University School of Medicine and received his first NIH R01 funding at the University of Chicago as a Research Assistant Professor. Dr. Zhao is an expert in research fields of lung biology, bioactive lysophospholipid, and protein ubiquitination. His research focuses on investigating the pathogenesis of lung diseases including acute respiratory distress syndrome, pulmonary fibrosis, pulmonary arterial hypertension, asthma, lung cancer, and COPD. The goal of Dr. Zhao’s laboratory research is to develop new therapeutic targets for treating lung diseases. Dr. Zhao is active in academic professional services as a reviewer, associate editor, and member of editorial boards of scientific journals and grant review study sections.

Part I: Lung Health and Pulmonary Diseases. Chapter 1. Antimicrobial Peptides in Lung Health and Pulmonary Diseases. Chapter 2. Alveolar Epithelium in Lung Injury and Repair. Chapter 3. Environmental Toxicants in Lung Diseases. Chapter 4. Epigenetic Modifications of Histone in Lung Fibrosis. Chapter 5. Translational Potential of Hypoxia-inducible factor-2α Signaling in Pulmonary Hypertension. Part II: Research Strategies and Methods in Lung Biology and Pathophysiology. Chapter 6. Utility of Lung Organoids to Accelerate Our Understanding of Human Pulmonary Development and Diseases. Chapter 7. Establishment of Animal Models of Pulmonary Fibrosis. Chapter 8. Research Strategies for Investigating Protein Ubiquitination in Lung Diseases. Chapter 9. Peroxidative Metabolism of Lung Lipids in Pulmonary Health and Disease: Emphasis on Methods of Analysis of Oxidative Modification of Polyunsaturated Membrane Phospholipids. Part III: Pathogenesis and Therapies of COVID-19. Chapter 10. Renin-Angiotensin System (RAS) and COVID-19: Exploring the Impact, Inhibition, and Treatment Strategies. Chapter 11. COVID-19 Therapeutics: Challenges and Opportunities. Chapter 12. Clinical manifestations and pathogenesis of COVID-19 pulmonary disease. Part IV: Traditional Chinese Medicine in Lung Diseases. Chapter 13. Pulmonary Diseases and Traditional Chinese Medicine.